Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free ESPR Stock Alerts

Esperion Therapeutics (ESPR) Competitors

Esperion Therapeutics logo
$3.16 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$3.16 +0.00 (+0.13%)
As of 07/2/2026 05:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

ESPR vs. GMTX, IDYA, RGC, ELVN, and VERA

Should you buy Esperion Therapeutics stock or one of its competitors? MarketBeat compares Esperion Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Esperion Therapeutics include Gemini Therapeutics (GMTX), IDEAYA Biosciences (IDYA), Regencell Bioscience (RGC), Enliven Therapeutics (ELVN), and Vera Therapeutics (VERA). These companies are all part of the "pharmaceutical products" industry.

How does Esperion Therapeutics compare to Gemini Therapeutics?

Gemini Therapeutics (NASDAQ:GMTX) and Esperion Therapeutics (NASDAQ:ESPR) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

75.4% of Gemini Therapeutics shares are held by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are held by institutional investors. 12.9% of Gemini Therapeutics shares are held by company insiders. Comparatively, 1.6% of Esperion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Esperion Therapeutics had 2 more articles in the media than Gemini Therapeutics. MarketBeat recorded 2 mentions for Esperion Therapeutics and 0 mentions for Gemini Therapeutics. Esperion Therapeutics' average media sentiment score of 1.65 beat Gemini Therapeutics' score of 0.00 indicating that Esperion Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Gemini Therapeutics Neutral
Esperion Therapeutics Very Positive

Gemini Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the broader market. Comparatively, Esperion Therapeutics has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market.

Esperion Therapeutics has a consensus price target of $5.54, suggesting a potential upside of 75.32%. Given Esperion Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Esperion Therapeutics is more favorable than Gemini Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gemini Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Esperion Therapeutics
1 Sell rating(s)
6 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Esperion Therapeutics has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Esperion Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gemini TherapeuticsN/AN/A-$71.87M-$1.00N/A
Esperion Therapeutics$403.14M2.02-$22.68M-$0.06N/A

Esperion Therapeutics has a net margin of 0.12% compared to Gemini Therapeutics' net margin of 0.00%. Esperion Therapeutics' return on equity of -0.14% beat Gemini Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Gemini TherapeuticsN/A -38.78% -35.88%
Esperion Therapeutics 0.12%-0.14%0.12%

Summary

Esperion Therapeutics beats Gemini Therapeutics on 13 of the 15 factors compared between the two stocks.

How does Esperion Therapeutics compare to IDEAYA Biosciences?

Esperion Therapeutics (NASDAQ:ESPR) and IDEAYA Biosciences (NASDAQ:IDYA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

Esperion Therapeutics has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market. Comparatively, IDEAYA Biosciences has a beta of -0.09, suggesting that its stock price is 109% less volatile than the broader market.

Esperion Therapeutics has a net margin of 0.12% compared to IDEAYA Biosciences' net margin of 0.00%. Esperion Therapeutics' return on equity of -0.14% beat IDEAYA Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Esperion Therapeutics0.12% -0.14% 0.12%
IDEAYA Biosciences N/A -14.24%-13.09%

In the previous week, Esperion Therapeutics had 1 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 2 mentions for Esperion Therapeutics and 1 mentions for IDEAYA Biosciences. Esperion Therapeutics' average media sentiment score of 1.65 beat IDEAYA Biosciences' score of 0.63 indicating that Esperion Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Esperion Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
IDEAYA Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

47.4% of Esperion Therapeutics shares are owned by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are owned by institutional investors. 1.6% of Esperion Therapeutics shares are owned by company insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Esperion Therapeutics has higher revenue and earnings than IDEAYA Biosciences. Esperion Therapeutics is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Esperion Therapeutics$403.14M2.02-$22.68M-$0.06N/A
IDEAYA Biosciences$218.71M15.12-$113.70M-$1.60N/A

Esperion Therapeutics currently has a consensus price target of $5.54, suggesting a potential upside of 75.32%. IDEAYA Biosciences has a consensus price target of $50.69, suggesting a potential upside of 34.63%. Given Esperion Therapeutics' higher possible upside, research analysts clearly believe Esperion Therapeutics is more favorable than IDEAYA Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Esperion Therapeutics
1 Sell rating(s)
6 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
IDEAYA Biosciences
1 Sell rating(s)
1 Hold rating(s)
15 Buy rating(s)
0 Strong Buy rating(s)
2.82

Summary

Esperion Therapeutics beats IDEAYA Biosciences on 10 of the 16 factors compared between the two stocks.

How does Esperion Therapeutics compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Esperion Therapeutics (NASDAQ:ESPR) are both pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

In the previous week, Regencell Bioscience had 1 more articles in the media than Esperion Therapeutics. MarketBeat recorded 3 mentions for Regencell Bioscience and 2 mentions for Esperion Therapeutics. Esperion Therapeutics' average media sentiment score of 1.65 beat Regencell Bioscience's score of 0.08 indicating that Esperion Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Regencell Bioscience
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Esperion Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Esperion Therapeutics has a net margin of 0.12% compared to Regencell Bioscience's net margin of 0.00%. Regencell Bioscience's return on equity of 0.00% beat Esperion Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Regencell BioscienceN/A N/A N/A
Esperion Therapeutics 0.12%-0.14%0.12%

Regencell Bioscience has a beta of 1.84, meaning that its share price is 84% more volatile than the broader market. Comparatively, Esperion Therapeutics has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market.

0.1% of Regencell Bioscience shares are owned by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are owned by institutional investors. 2.0% of Regencell Bioscience shares are owned by insiders. Comparatively, 1.6% of Esperion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Regencell Bioscience has higher earnings, but lower revenue than Esperion Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regencell BioscienceN/AN/A-$3.58MN/AN/A
Esperion Therapeutics$403.14M2.02-$22.68M-$0.06N/A

Esperion Therapeutics has a consensus target price of $5.54, indicating a potential upside of 75.32%. Given Esperion Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Esperion Therapeutics is more favorable than Regencell Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Regencell Bioscience
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Esperion Therapeutics
1 Sell rating(s)
6 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Esperion Therapeutics beats Regencell Bioscience on 8 of the 13 factors compared between the two stocks.

How does Esperion Therapeutics compare to Enliven Therapeutics?

Enliven Therapeutics (NASDAQ:ELVN) and Esperion Therapeutics (NASDAQ:ESPR) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

Enliven Therapeutics has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, Esperion Therapeutics has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are held by institutional investors. 3.0% of Enliven Therapeutics shares are held by company insiders. Comparatively, 1.6% of Esperion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Enliven Therapeutics had 5 more articles in the media than Esperion Therapeutics. MarketBeat recorded 7 mentions for Enliven Therapeutics and 2 mentions for Esperion Therapeutics. Esperion Therapeutics' average media sentiment score of 1.65 beat Enliven Therapeutics' score of 0.94 indicating that Esperion Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Enliven Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Esperion Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Esperion Therapeutics has a net margin of 0.12% compared to Enliven Therapeutics' net margin of 0.00%. Esperion Therapeutics' return on equity of -0.14% beat Enliven Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Enliven TherapeuticsN/A -21.04% -20.41%
Esperion Therapeutics 0.12%-0.14%0.12%

Esperion Therapeutics has higher revenue and earnings than Enliven Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Enliven Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enliven TherapeuticsN/AN/A-$103.69M-$1.67N/A
Esperion Therapeutics$403.14M2.02-$22.68M-$0.06N/A

Enliven Therapeutics presently has a consensus price target of $67.83, suggesting a potential upside of 36.16%. Esperion Therapeutics has a consensus price target of $5.54, suggesting a potential upside of 75.32%. Given Esperion Therapeutics' higher probable upside, analysts clearly believe Esperion Therapeutics is more favorable than Enliven Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enliven Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
Esperion Therapeutics
1 Sell rating(s)
6 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Esperion Therapeutics beats Enliven Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Esperion Therapeutics compare to Vera Therapeutics?

Vera Therapeutics (NASDAQ:VERA) and Esperion Therapeutics (NASDAQ:ESPR) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

In the previous week, Vera Therapeutics and Vera Therapeutics both had 2 articles in the media. Esperion Therapeutics' average media sentiment score of 1.65 beat Vera Therapeutics' score of 1.11 indicating that Esperion Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vera Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Esperion Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Esperion Therapeutics has a net margin of 0.12% compared to Vera Therapeutics' net margin of 0.00%. Esperion Therapeutics' return on equity of -0.14% beat Vera Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Vera TherapeuticsN/A -74.86% -60.18%
Esperion Therapeutics 0.12%-0.14%0.12%

Vera Therapeutics currently has a consensus target price of $78.00, indicating a potential upside of 89.32%. Esperion Therapeutics has a consensus target price of $5.54, indicating a potential upside of 75.32%. Given Vera Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Vera Therapeutics is more favorable than Esperion Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vera Therapeutics
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.75
Esperion Therapeutics
1 Sell rating(s)
6 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Esperion Therapeutics has higher revenue and earnings than Vera Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vera TherapeuticsN/AN/A-$299.61M-$5.54N/A
Esperion Therapeutics$403.14M2.02-$22.68M-$0.06N/A

Vera Therapeutics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market. Comparatively, Esperion Therapeutics has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market.

99.2% of Vera Therapeutics shares are held by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are held by institutional investors. 15.9% of Vera Therapeutics shares are held by insiders. Comparatively, 1.6% of Esperion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Esperion Therapeutics beats Vera Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Esperion Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ESPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ESPR vs. The Competition

Export
MetricEsperion TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$814.31M$3.02B$6.82B$12.56B
Dividend YieldN/A2.02%2.68%6.63%
P/E Ratio-52.6720.0627.9224.56
Price / Sales2.02348.75533.5197.33
Price / CashN/A57.2848.5958.15
Price / Book-2.514.3210.916.45
Net Income-$22.68M$64.45M$3.57B$336.71M
7 Day Performance-0.32%3.04%2.21%1.37%
1 Month Performance0.64%5.81%4.58%1.67%
1 Year Performance169.85%29.10%33.45%24.05%

Esperion Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ESPR
Esperion Therapeutics
2.7912 of 5 stars		$3.16
flat		$5.54
+75.3%		+174.8%$814.31M$403.14MN/A200
GMTX
Gemini Therapeutics
N/A$74.78
+6.6%		N/A+46.6%$3.24BN/AN/A30
IDYA
IDEAYA Biosciences
3.5696 of 5 stars		$36.55
-0.5%		$50.69
+38.7%		+71.8%$3.23B$218.71MN/A80
RGC
Regencell Bioscience
0.3246 of 5 stars		$6.19
-4.5%		N/A-38.5%$3.20BN/AN/A10
ELVN
Enliven Therapeutics
3.1581 of 5 stars		$50.85
+1.5%		$64.50
+26.8%		+141.4%$3.05BN/AN/A50

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ESPR) was last updated on 7/3/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel